Unique ID issued by UMIN | UMIN000006079 |
---|---|
Receipt number | R000007195 |
Scientific Title | A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib |
Date of disclosure of the study information | 2011/07/30 |
Last modified on | 2018/02/19 15:13:23 |
A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib
A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib
A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib
A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib
Japan |
non-small cell lung cancer
Pneumology |
Malignancy
NO
Covering analysis including effectiveness and safety of treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and as 2nd-line Erlotinib for patients with StageIIIB/IV non- squamous non-small cell lung cancer
Safety,Efficacy
Time to Treatment Failure
2nd PFS, Adverse events, Overall survival,
Observational
Not applicable |
Not applicable |
Male and Female
1)histologically or cytologically confirmed non-squamous non-small-cell lung cancer
2) stage IIIB/IV or postoperative recurrence patients
3)chemotheraoy naive patients
4)Patients providing written informed consent
1)Inappropriate patients for this study judged by the physicians
44
1st name | |
Middle name | |
Last name | Yoko Shibata |
Yamagata University School of Medicine
Department of Cardiology, Pulmonology, and Nephrology
2-2-2 Iida-Nishi, Yamagata-shi,Yamagata 990-9585, Japan
1st name | |
Middle name | |
Last name |
Yamagata University School of Medicine
Department of Cardiology, Pulmonology, and Nephrology
2-2-2 Iida-Nishi, Yamagata-shi,Yamagata 990-9585, Japan
023-628-5302
Yamagata University School of Medicine
None
Self funding
NO
2011 | Year | 07 | Month | 30 | Day |
Unpublished
Terminated
2011 | Year | 05 | Month | 16 | Day |
2011 | Year | 07 | Month | 01 | Day |
Covering analysis including effectiveness and safety of treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and as 2nd-line Erlotinib for patients with StageIIIB/IV non- squamous non-small cell lung cancer
2011 | Year | 07 | Month | 29 | Day |
2018 | Year | 02 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007195
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |